XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...

Diagnostic performance of 18F-flotufolastat PET/CT compared with conventional imaging for detection of pelvic lymph node metastases in men with newly diagnosed prostate cancer: Descriptive post-hoc ...

Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who ...

Please provide your email address to receive an email when new articles are posted on . Many men with metastatic hormone-sensitive prostate cancer have not received recommended first-line treatment.

Findings showed darolutamide reduced the risk of radiographic progression or death by 46% compared with placebo. The Food and Drug Administration (FDA) has approved Nubeqa ® (darolutamide), an ...

(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...

Prostate cancer is one of the leading causes of cancer-related death in men, and some experts project the number of cases to ...

Former President Biden has been diagnosed with an aggressive form of prostate cancer. Among men in the U.S., prostate cancer is the most common cancer and the second leading cause of cancer deaths.

Vasomotor symptoms (VMS) including hot flashes are a common complaint among men undergoing androgen deprivation therapy (ADT) for prostate cancer. Although the symptoms are more widely associated with ...

The journey through prostate cancer treatment marks a significant chapter in many men’s lives, with surgery often serving as a pivotal turning point toward recovery. While the removal of cancerous ...